TAK

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.10
Percentage change 0.65	%

Peers: PFE MRK BMY GSK SNY LLY AZN JNJ NVS ABBV

| Held by: FVD PPH APIE AVDE GINX VEU CVY AVSD DFIC DFAX

Scroll to Statements

Index	-	P/E	34.68	EPS (ttm)	0.43	Insider Own	0.00%	Shs Outstand	3.17B	Perf Week	6.31%
Market Cap	46.75B	Forward P/E	29.75	EPS next Y	0.50	Insider Trans	-	Shs Float	3.17B	Perf Month	-2.54%
Income	1.36B	PEG	1.26	EPS next Q	-0.18	Inst Own	5.03%	Short Float	0.16%	Perf Quarter	12.99%
Sales	30.22B	P/S	1.55	EPS this Y	-1.90%	Inst Trans	-1.38%	Short Ratio	2.59	Perf Half Y	4.95%
Book/sh	14.89	P/B	0.99	EPS next Y	71.21%	ROA	1.38%	Short Interest	5.03M	Perf Year	11.45%
Cash/sh	0.99	P/C	14.87	EPS next 5Y	27.46%	ROE	2.87%	52W Range	12.57 - 15.37	Perf YTD	11.37%
Dividend Est.	0.65 (4.44%)	P/FCF	8.26	EPS past 5Y	-12.87%	ROI	1.77%	52W High	-4.07%	Beta	0.29
Dividend TTM	0.33 (2.21%)	Quick Ratio	0.72	Sales past 5Y	-0.57%	Gross Margin	52.93%	52W Low	17.26%	ATR (14)	0.33
Dividend Ex-Date	Sep 30, 2024	Current Ratio	1.31	EPS Y/Y TTM	6.40%	Oper. Margin	13.48%	RSI (14)	53.34	Volatility	1.84% 1.91%
Employees	49281	Debt/Eq	0.65	Sales Y/Y TTM	1.92%	Profit Margin	4.51%	Recom	1.94	Target Price	16.76
Option/Short	Yes / Yes	LT Debt/Eq	0.63	EPS Q/Q	-78.80%	Payout	163.50%	Rel Volume	0.90	Prev Close	14.65
Sales Surprise	0.42%	EPS Surprise	-42.67%	Sales Q/Q	-0.06%	Earnings	Jan 30 AMC	Avg Volume	1.95M	Price	14.74
SMA20	0.35%	SMA50	1.57%	SMA200	5.20%	Trades		Volume	1,433,769	Change	0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy	$20
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform	$21 → $24
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform	$19.50
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

Apr-16-25 11:40AM	TAK vs. DSNKY: Which Stock Is the Better Value Option? (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
07:25AM	NMPA approves BBM and Takeda Chinas haemophilia B therapy (Pharmaceutical Technology)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
11:53AM	Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs (The Wall Street Journal)
07:15AM	Loading…
Apr-08-25 07:15AM	BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 (ACCESSWIRE)
Apr-04-25 09:40AM	Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? (Zacks)
Apr-03-25 11:25AM	Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (Seeking Alpha)
Apr-01-25 02:27PM	Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns (Seeking Alpha)
Mar-31-25 11:40AM	TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? (Zacks)
Mar-28-25 09:41AM	Takeda Canada says Health Canada expands marketing authorization for HyQvia (TipRanks)
Mar-27-25 09:30AM	Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) (PR Newswire)
Mar-24-25 03:00PM	ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? (Zacks)
Mar-19-25 09:40AM	Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now? (Zacks)
Mar-13-25 04:00AM	Takedas $770M deal deepens Big Pharmas omics push (Pharma Voice)
12:01PM	Loading…
Mar-03-25 12:01PM	Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer (Benzinga)
10:25AM	Takeda and Protagonist report topline outcomes from trial of rusfertide (Clinical Trials Arena)
09:40AM	Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? (Zacks)
06:45AM	Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera (Business Wire)
06:29AM	Protagonist says Takeda-partnered drug succeeds in rare blood cancer (BioPharma Dive)
Feb-27-25 08:43AM	Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
Feb-25-25 07:11PM	Takeda broadens its deal with BridGene for up to $770m (Pharmaceutical Technology)
10:09AM	EMA approves Takedas Takhzyro pre-filled pen option for HAE (Pharmaceutical Technology)
Feb-24-25 03:01AM	The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) (PR Newswire)
Feb-15-25 02:43PM	Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025? (Insider Monkey)
Feb-14-25 09:40AM	Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? (Zacks)
Feb-12-25 10:04AM	BBI announces $31m facility for Shire to enhance asset finance (Leasing Life)
Feb-10-25 03:00AM	Are orexins the next golden child of neuroscience? (Pharma Voice)
Jan-30-25 10:14AM	Takeda announces appointment of Julie Kim as CEO (Pharmaceutical Technology)
06:22AM	Christophe Weber, veteran Takeda CEO, to retire next year (BioPharma Dive)
02:04AM	Loading…
02:04AM	Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 (Business Wire)
01:35AM	Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth (Business Wire)
Jan-29-25 08:00AM	Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age (PR Newswire)
Jan-28-25 10:24AM	Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights (Benzinga)
Jan-21-25 08:00AM	Takeda Recognized as a Top Employer in Canada for Third Consecutive Year (PR Newswire)
08:00AM	Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire)
06:43AM	Health Canada gives Takedas mCRC capsules market authorisation (Pharmaceutical Technology)
Jan-20-25 08:00AM	Takeda's FRUZAQLA (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC) (PR Newswire)
Jan-02-25 04:03PM	Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025. (Barrons.com)
Dec-27-24 07:59AM	Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency (Benzinga)
01:00AM	Takeda Announces Approval of HYQVIA 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia (Business Wire)
Dec-19-24 08:02AM	Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative (PR Newswire)
06:32AM	Takeda Announces Subsidiary Liquidation and Merger Completion (TipRanks)
Dec-12-24 07:00PM	HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) (GlobeNewswire)
05:30PM	Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas (Business Wire)
Dec-04-24 06:07AM	Novavax sells Czech plant to Novo; Relay licenses out a cancer drug (BioPharma Dive)
04:31AM	Takeda licensed for anaemia therapy by Keros Therapeutics (Pharmaceutical Technology)
Dec-03-24 12:37PM	Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst (Benzinga)
07:00AM	Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics (Business Wire)
07:00AM	Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire)
06:30AM	Takedas Strong FY2024 H1 Boosts Full-Year Outlook (TipRanks)
Nov-30-24 04:29PM	Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now? (Insider Monkey)
Nov-29-24 08:08AM	Takeda Canada co-sponsors grant to boost IBD clinical research (Clinical Trials Arena)
Nov-21-24 11:30PM	HUTCHMED Announces Launch by Takeda of FRUZAQLA (fruquintinib) in Japan (GlobeNewswire)
08:22AM	Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies (Pharmaceutical Technology)
Nov-13-24 11:46AM	Why this major drugmaker no longer has an IT department (Fortune)
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-04-24 08:01AM	New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD (PR Newswire)
Oct-31-24 04:30AM	HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda (GlobeNewswire)
02:05AM	Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook (Business Wire)
Oct-30-24 09:00AM	What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings (GuruFocus.com)
Oct-25-24 07:04AM	Takeda and BMC partner to decarbonise US healthcare sector (Pharmaceutical Technology)
Oct-24-24 08:00AM	Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem (Business Wire)
Oct-23-24 03:05AM	Dengue is spreading and Sanofi is pulling the U.S. markets only vaccine. Whats next? (Pharma Voice)
Oct-22-24 08:54AM	Deko and Shire Leasing partner to offer B2B leasing at checkout (Leasing Life)
Oct-17-24 02:32PM	Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside (Benzinga)
Oct-15-24 07:02PM	Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical (GuruFocus.com)
Oct-09-24 05:36PM	WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com)
Oct-03-24 09:40AM	Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? (Zacks)
Sep-27-24 06:32AM	Tempus AI expands oncology collaboration with Takeda (Pharmaceutical Technology)
Sep-26-24 08:30AM	Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development (Business Wire)
Sep-24-24 06:33AM	Takedas FRUZAQLA approved in Japan for advanced colorectal cancer (Pharmaceutical Technology)
03:00AM	Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer (Business Wire)
03:00AM	HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda (GlobeNewswire)
Sep-23-24 06:32AM	MHRA approves Takedas fruquintinib for metastatic colorectal cancer (Pharmaceutical Technology)
Sep-22-24 03:55AM	Takeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now (Insider Monkey)
Sep-19-24 08:00AM	Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024 (Business Wire)
06:33AM	Lupin and Takeda to commercialise Vonoprazan in India (Pharmaceutical Technology)
Sep-18-24 10:00AM	Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries (Business Wire)
Sep-17-24 09:40AM	Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now? (Zacks)
Sep-16-24 08:39AM	Vatroslav Mateljic Appointed General Manager of Takeda Canada (PR Newswire)
Sep-11-24 05:38AM	Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada (Bloomberg)
Sep-10-24 08:15AM	Investors are waking up to Centessas sleepiness drug (BioPharma Dive)
Aug-28-24 12:31PM	Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers (Insider Monkey)
Aug-08-24 06:33AM	Takedas ADZYNMA gains EU approval for cTTP treatment (Pharmaceutical Technology)
Aug-07-24 02:29PM	Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? (Benzinga)
06:45AM	Takeda Receives European Commission Approval for ADZYNMA (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Business Wire)
Aug-05-24 11:32PM	Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix (Bloomberg)
03:36PM	Japans Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish. (Barrons.com)
Aug-01-24 04:52AM	Takedas revenue climbs by 14.1% in Q1 FY2024 (Pharmaceutical Technology)
Jul-31-24 02:06AM	Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline (Business Wire)
Jul-29-24 06:00AM	3 Biotech Stocks to Buy on the Dip: July 2024 (InvestorPlace)
Jul-15-24 08:55AM	Shire Leasing accredited to deliver Growth Guarantee Scheme (Leasing Life)
Jul-08-24 06:54PM	OPKO Health, Inc. (OPK): Most Shorted Stock Loved by Analysts Right Now? (Insider Monkey)
10:53AM	Polpharma looks to challenge Takedas Entyvio in IBD (Pharmaceutical Technology)
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
Jun-26-24 03:05AM	Takeda Announces New Assignments of Directors (Business Wire)
Jun-24-24 06:32AM	Takeda reports positive data from Phase IIb trial of ITP treatment (Clinical Trials Arena)
04:42AM	EC approves Takedas Fruzaqla for metastatic colorectal cancer (Pharmaceutical Technology)
03:00AM	Takeda Announces Approval of LIVTENCITY (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies (Business Wire)

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Giles Richard Platford	President, Plasma-Derived Ther	Aug 23 '24	Proposed Sale	14.94	19,073	284,951		Aug 22 08:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Takeda Pharmaceutical Co ADR

Upgrade your FINVIZ experience